Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions (CLL14)

Phase 3 first-line venetoclax-obinutuzumab vs chlorambucil-obinutuzumab in patients with CLL and coexisting conditions. Fixed-duration Ven-O produced high MRD-undetectable rates and a PFS benefit, with subsequent MRD-dynamics papers (Al-Sawaf JCO 2021; 6-year Blood 2024). Level 2.

N Engl J MedPubMed 31166681